Maximum tolerated dose and/or recommended Phase 2 dose Continuous up to one year [clinicaltrials_resource:9e55519205314beddfe190a101cdff1b]
Combination Pomalidomide, low-dose Dexamethasone, and Marizomib:
clinicaltrials_vocabulary:secondary outcome [clinicaltrials_vocabulary:clinicaltrials_vocabulary:secondary-outcome]
Maximum tolerated dose and/or recommended Phase 2 dose Continuous up to one year [clinicaltrials_resource:9e55519205314beddfe190a101cdff1b]
Combination Pomalidomide, low-dose Dexamethasone, and Marizomib:
Bio2RDF identifier
9e55519205314beddfe190a101cdff1b
Bio2RDF namespace
clinicaltrials_resource
Bio2RDF uri
http://bio2rdf.org/clinicaltrials_resource:9e55519205314beddfe190a101cdff1b
measure [clinicaltrials_vocabulary:measure]
Maximum tolerated dose and/or recommended Phase 2 dose
time frame [clinicaltrials_vocabulary:time-frame]
Continuous up to one year
description
Combination Pomalidomide, low-dose Dexamethasone, and Marizomib:
identifier
clinicaltrials_resource:9e55519205314beddfe190a101cdff1b
title
Maximum tolerated dose and/or recommended Phase 2 dose Continuous up to one year
@en
type
label
Maximum tolerated dose and/or ...... 5519205314beddfe190a101cdff1b]
@en